Drug Profile
Teriparatide biosimilar - Virchow Group
Alternative Names: Bonista; OsteotideLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Virchow Group
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 20 May 2015 Virchow Group signed a memorandum of understanding with Sun Pharmaceutical Industries to market its indigenously developed recombinant therapeutic protein for the treatment of Osteoporosis before May 2015 (Virchow Group website, May 2015)
- 25 Mar 2015 Sun Pharmaceutical Industries has merged with Ranbaxy forming Sun Pharma